Evidence map›Paper›PMID 29713898›Full record

ReviewCurrent oncology reports2018

Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.

Vivian Y Chang, Jessica J Wang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Brazilian Cardio-oncology Guideline - 2020.Arquivos brasileiros de cardiologia · 2020
    Guideline
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Anthracycline Toxicity: Light at the End of the Tunnel?Annual review of pharmacology and toxicology · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Cardio-Oncology in Childhood: State of the Art.Current oncology reports · 2022
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Vivian Y ChangDepartment of Pediatrics, Division of Hematology/Oncology, University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA, 90095, USA.
Jessica J WangDepartment of Medicine, Division of Cardiology, University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA, 90095, USA. jessicawang@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

Functional Validation of Myh14 in Stress-Induced Cardiac Remodeling.K08HL133491 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WANG, JESSICA J · 2017 to 2021
$875k
NHLBI NIH HHS K08 HL133491
6 · The paper itself

Abstract

purpose of reviewThe goal of this review is to summarize current understanding of pharmacogenetics and pharmacogenomics in chemotherapy-induced cardiotoxicity. RECENT

findingsMost of the studies rely on in vitro cytotoxic assays. There have been several smaller scale candidate gene approaches and a handful of genome-wide studies linking genetic variation to susceptibility to chemotherapy-induced cardiotoxicity. Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended. There is no recommendation regarding testing in adults. There is clear evidence pointing to the role of pharmacogenetics and pharmacogenomics in cardiotoxicity susceptibility to chemotherapeutic agents. Larger scale studies are needed to further identify susceptibility markers and to develop pharmacogenomics-based risk profiling to improve quality of life and life expectancy in cancer survivors.

Indexed as

AnimalsAntineoplastic AgentsCardiotoxicityDaunorubicinDoxorubicinGenetic TestingHumansMicePharmacogeneticsPolymorphism, Single NucleotideReceptors, Retinoic AcidRetinoic Acid Receptor gammaAntineoplastic AgentsDaunorubicinDoxorubicinReceptors, Retinoic AcidRetinoic Acid Receptor gammaChemotherapy-induced cardiomyopathyChemotherapy-induced cardiotoxicityPharmacogenetics of cancerPharmacogenomics of cancer

Identifiers

PMID29713898
PMCPMC6371783
OpenAlexW2800628510

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.